ArticleFrontiers in pharmacology2026
Crocins ameliorate acute kidney injury in glycerol-induced rhabdomyolysis by targeting the PLIN1/PPARs signaling pathway.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rhabdomyolysis (RM) is a potentially life-threatening syndrome characterized by skeletal muscle damage, with acute kidney injury (AKI) being its most severe complication. Currently, no effective treatment exists for RM-induced AKI. Crocins, the major bioactive constituents extracted from the stigma of Objectives: This study aimed to explore the pharmacological effect and possible mechanism of crocins in the treatment of RM-induced AKI. Method: Network analysis was first applied to predict potential targets of crocins against RM. A rat model of hypertonic glycerol-induced RM was then established to evaluate pharmacological effect, including assessment of muscle and renal pathology, inflammatory cytokines, biochemical markers, and oxidative stress-related enzymes. Tandem mass tag-based quantitative proteomics was further employed to identify key disease targets. Molecular docking was then conducted to validate potential target interactions of crocins in RM-induced AKI treatment. Results: Animal experiments demonstrated that crocins alleviated muscle and renal injuries by inhibiting inflammation and oxidative stress while preserving hepatic and renal functions. Proteomic analysis identified perilipin 1 (PLIN1) as a critical candidate biomarker mediating these effects. Both network analysis and proteomics indicated that the peroxisome proliferator-activated receptors (PPARs) signaling pathway was closely involved in protective mechanism. Furthermore, Western blotting confirmed that crocins exerted pharmacological effect through regulating the PLIN1/PPARs signaling pathway. Molecular docking revealed that the best docking activities were demonstrated by crocin I/II-PLIN1, crocin I-PPARα, and crocin II-PPARγ. Conclusion: Crocins mitigated RM-induced AKI primarily by suppressing inflammation and oxidative stress via the PLIN1/PPARs signaling pathway. These findings provide a scientific and theoretical basis for the potential clinical application of crocins in treating RM-induced AKI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.